The ECOG-ACRIN Cancer Research Group’s definitive phase III trial, E2805, showed no disease-free survival benefit with the use of either sorafenib or sunitinib as adjuvant treatment for locally advanced renal cell carcinoma. The results of this study were published online in The Lancet on March 8, 2016. The trial was supported by the Cancer Trials Evaluation Program of the National Cancer Institute. The study protocol is available at the link below.
|Trial Educational Materials|
|NCI-MATCH / EAY131 for Researchers|
|ECOG Performance Status|